PressReleases from SanoLiBio GmbH

About SanoLiBio GmbHSanoLiBio focuses on the ultra-high enrichment of rare cells, such as circulating tumor cells, taken from liquid biopsy. The overall liquid biopsy market will grow to USD 10,7bn by 2026, a CAGR of 24.2%. Thereof, the sub-segment of cancer will grow with a CAGR of 52,4%. (Source: BCC Research, Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets October 2017).The Medtech-Startup was founded 2017 located in Munich at the Biotech-Hotspot in Europe. CEO is Dr. Stefan Schreier who leads the company together with Timo Peter (COO) and Ulrich Lang (CTO).About?Walderbach?The company will introduce its fully automated cell enrichment platform, named "Walderbach", as a new benchmark in rare cell isolation from 2020 onwards internationally. The platform ...

all PressReleases

All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 147

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.